JD Health International Inc. (HKG:6618)
Hong Kong · Delayed Price · Currency is HKD | Market Cap | 123.31B -39.5% |
| Revenue (ttm) | 91.25B +21.4% |
| Net Income | 7.18B +31.7% |
| EPS | 2.24 +31.0% |
| Shares Out | 3.19B |
| PE Ratio | 17.26 |
| Forward PE | 14.29 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 9,126,243 |
| Open | 37.70 |
| Previous Close | 38.04 |
| Day's Range | 37.70 - 39.02 |
| 52-Week Range | 31.84 - 71.70 |
| Beta | 1.18 |
| Analysts | Strong Buy |
| Price Target | 68.33 (+76.75%) |
| Earnings Date | Aug 13, 2026 |
About JD Health International
JD Health International Inc., an investment holding company, engages in the operation of an online healthcare platform in the People’s Republic of China. It provides online medical consultation, hospital or doctor referral, health check-ups, genetic testing, and beauty care services, as well as internet healthcare, health management, intelligent healthcare, advertising, and technical services. The company also offers home care services, including wound care, blood tests and diagnostics, post-operative care, and medical escort; online medical in... [Read more]
Financial Performance
In 2025, JD Health International's revenue was 73.44 billion, an increase of 26.28% compared to the previous year's 58.16 billion. Earnings were 5.38 billion, an increase of 29.16%.
Financial numbers in CNY Financial StatementsAnalyst Summary
According to 18 analysts, the average rating for 6618 stock is "Strong Buy." The 12-month stock price target is $68.33, which is an increase of 76.75% from the latest price.
News
JD Health International Earnings Call Transcript: H1 2026
Revenue grew to CNY 40.9 billion in H1 2026, with operating profit up 40.3% year-over-year and gross margin improving for the ninth consecutive quarter. AI integration and supply chain strength drove efficiency, while regulatory changes impacted nutrition and supplements.
JD Health International Earnings release: H1 2026
JD Health International released its H1 2026 earnings on August 13, 2026, summarizing the period's financial results.
JD Health International Earnings Call Transcript: H2 2025
Revenue grew 26.3% year-over-year to RMB 73.4 billion, with non-IFRS profit up 36.3% and gross margin at 24.8%. Strategic partnerships, AI-driven services, and expanded product offerings fueled growth, while the company sees significant market potential ahead.
JD Health International Earnings release: H2 2025
JD Health International released its H2 2025 earnings on March 5, 2026, summarizing the period's financial results.
JD Health International Annual report: H2 2025
JD Health International has published its H2 2025 annual report on March 5, 2026.
